Treatment Options in Hepatitis C. - Wikidata - wikimedia - TriplyDB

Treatment Options in Hepatitis C.

Treatment Options in Hepatitis C.

http://www.wikidata.org/entity/Q39112237

about

Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk The Treatment of Hepatitis C- An Introduction to the Use of New Medicines.Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents.

P2860

Q41934445-D833FA17-81B2-4218-AA7B-9E8B62A84DBE Q42360359-C54E0E4F-5133-4782-8FE9-F005C728C97A Q55020469-08DA47F0-C560-4F82-8D5F-0EFC2606B68A

P2860

Treatment Options in Hepatitis C.

http://www.wikidata.org/entity/Q39112237

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Treatment Options in Hepatitis C.

@en

Treatment Options in Hepatitis C.

@nl

type

label

Treatment Options in Hepatitis C.

@en

Treatment Options in Hepatitis C.

@nl

prefLabel

Treatment Options in Hepatitis C.

@en

Treatment Options in Hepatitis C.

@nl

P1433

Q39112237-641323BA-5BB7-44BA-B7EE-9D37BA72DE8B

P1476

Q39112237-E482DC81-4844-4683-A6F7-994F98DC98F1

P2860

Q39112237-0146AFB7-87AC-4B4E-9469-2A8F1CB58B7E

Q39112237-02CFB383-F7CE-4127-B76A-96295A34A7AB

Q39112237-06C77F33-912A-4F49-B5F6-A92536C3EFB3

Q39112237-0A8576E6-C6F8-461B-BBC6-07C701613FDA

Q39112237-0AB7A176-ED14-45A4-9D2E-84A78B7AC927

Q39112237-0BA1BDF0-15EB-4581-B7B0-CE2C86A8A37C

Q39112237-1133B894-CC6E-4F2C-9206-C8370761F5B6

Q39112237-13331CC4-B54A-46E1-BCBA-F04F6D051282

Q39112237-146AE2A3-B3A0-4FC9-BD2F-B7697832C438

Q39112237-164A3999-7F67-44B4-8D87-0F972B7F64AE

P304

Q39112237-0A77A25A-F926-4067-8EE2-A199C7D35714

P31

Q39112237-AD12E66B-80E6-4E87-999B-2346534157BA

P356

Q39112237-1AC806E2-0E5C-41C8-80E3-5D13C9662BC7

P433

Q39112237-0747151C-B16C-4CE4-A068-5060A344F42B

P478

Q39112237-40BD60FC-FEB8-4BB1-9977-CBEA4FA09909

P50

Q39112237-AFD946FB-34C7-416B-908C-A4AAEF9CCE2A

P577

Q39112237-D20A57A4-9730-417A-AD5D-B5E6AAFD6183

P698

Q39112237-A6552AA6-7AE7-4B75-BFFB-F6ABBAD06C6B

P932

Q39112237-4C81EB5B-E285-450C-A282-10FF69FF1FD6

P356

ARZTEBL.2017.0011

P1433

Deutsches Ärzteblatt international

P1476

Treatment Options in Hepatitis C.

@en

P2860

Emerging therapies for the treatment of hepatitis C

Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

P304

11-21

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3238/ARZTEBL.2017.0011

http://www.w3.org/2001/XMLSchema#string

P433

1-02

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28143635

http://www.w3.org/2001/XMLSchema#string

P932

5373481

http://www.w3.org/2001/XMLSchema#string